Mimicking chronic glaucoma over 6 months with a single intracameral injection of dexamethasone/fibronectin-loaded PLGA microspheres.
Glaucoma animal model
PLGA microspheres
intraocular pressure
multiloaded
neurodegeneration
Journal
Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
entrez:
29
7
2022
pubmed:
30
7
2022
medline:
2
8
2022
Statut:
ppublish
Résumé
To create a chronic glaucoma animal model by a single intracameral injection of biodegradable poly lactic-co-glycolic acid (PLGA) microspheres (Ms) co-loaded with dexamethasone and fibronectin (MsDexaFibro). MsDexaFibro were prepared by a water-in-oil-in-water emulsion method including dexamethasone in the organic phase and fibronectin in the inner aqueous phase. To create the chronic glaucoma model, an interventionist and longitudinal animal study was performed using forty-five Long Evans rats (4-week-old). Rats received a single intracameral injection of MsDexafibro suspension (10%w/v) in the right eye. Ophthalmological parameters such as clinical signs, intraocular pressure (IOP), neuro-retinal functionality by electroretinography (ERG), retinal structural analysis by optical coherence tomography (OCT), and histology were evaluated up to six months. According to the results obtained, the model proposed was able to induce IOP increasing in both eyes over the study, higher in the injected eyes up to 6 weeks (p < 0.05), while preserving the ocular surface. OCT quantified progressive neuro-retinal degeneration (mainly in the retinal nerve fiber layer) in both eyes but higher in the injected eye. Ganglion cell functionality decreased in injected eyes, thus smaller amplitudes in PhNR were detected by ERG. In conclusion, a new chronic glaucoma animal model was created by a single injection of MsDexaFibro very similar to open-angle glaucoma occurring in humans. This model would impact in different fields such as ophthalmology, allowing long period of study of this pathology; pharmacology, evaluating the neuroprotective activity of active compounds; and pharmaceutical technology, allowing the correct evaluation of the efficacy of long-term sustained ocular drug delivery systems.
Identifiants
pubmed: 35904152
doi: 10.1080/10717544.2022.2096712
pmc: PMC9341346
doi:
Substances chimiques
Fibronectins
0
Glycols
0
Water
059QF0KO0R
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2357-2374Références
Front Endocrinol (Lausanne). 2019 Apr 29;10:265
pubmed: 31110493
Curr Eye Res. 1981;1(7):391-6
pubmed: 7318492
Expert Opin Drug Discov. 2017 Mar;12(3):261-270
pubmed: 28075618
Invest Ophthalmol Vis Sci. 2021 Oct 4;62(13):9
pubmed: 34643665
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
Vestn Oftalmol. 2017;133(2):39-45
pubmed: 28524138
Curr Opin Ophthalmol. 2003 Apr;14(2):86-90
pubmed: 12698048
PLoS One. 2016 Oct 26;11(10):e0165326
pubmed: 27783649
Expert Opin Biol Ther. 2005 Nov;5(11):1443-52
pubmed: 16255648
Exp Eye Res. 2018 Jun;171:12-29
pubmed: 29526796
J Biomed Mater Res B Appl Biomater. 2019 May;107(4):1150-1158
pubmed: 30281905
Optom Vis Sci. 2008 Jun;85(6):406-16
pubmed: 18521010
J Control Release. 2017 Nov 28;266:365
pubmed: 29223387
J Antimicrob Chemother. 2001 Jun;47(6):829-35
pubmed: 11389115
BMC Neurosci. 2006 Oct 03;7:66
pubmed: 17018142
J Pharm Pharm Sci. 2014;17(4):541-53
pubmed: 25579433
Front Aging Neurosci. 2017 Jul 06;9:214
pubmed: 28729832
Invest Ophthalmol Vis Sci. 2011 Mar 25;52(3):1671-5
pubmed: 20926815
Sci Rep. 2020 Jun 17;10(1):9815
pubmed: 32555351
Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):2140-51
pubmed: 27100161
Mol Neurodegener. 2014 Apr 27;9:14
pubmed: 24767545
Pharmaceutics. 2021 Feb 08;13(2):
pubmed: 33567776
Am J Pathol. 2017 Apr;187(4):713-723
pubmed: 28167045
Doc Ophthalmol. 2017 Apr;134(2):111-128
pubmed: 28243926
J Cell Sci. 2002 Oct 15;115(Pt 20):3861-3
pubmed: 12244123
Exp Eye Res. 1997 Jan;64(1):85-96
pubmed: 9093024
Vision Res. 2009 Jan;49(1):115-26
pubmed: 18952118
Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1448-57
pubmed: 16565378
Surv Ophthalmol. 2018 May - Jun;63(3):296-306
pubmed: 28986311
Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6700-6711
pubmed: 27942722
Drug Discov Today. 2019 Aug;24(8):1644-1653
pubmed: 30928691
Drug Deliv. 2021 Dec;28(1):2427-2446
pubmed: 34763590
J Control Release. 2017 Nov 28;266:187-197
pubmed: 28947395
BMJ. 2017 Jun 1;357:j2358
pubmed: 28572302
Am J Ophthalmol. 2000 Oct;130(4):429-40
pubmed: 11024415
Exp Eye Res. 2015 Dec;141:164-70
pubmed: 25998495
Acta Ophthalmol. 2019 May;97(3):e331-e340
pubmed: 30549197
Prog Retin Eye Res. 2014 Nov;43:17-75
pubmed: 25038518
Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1183-92
pubmed: 26975030
Curr Eye Res. 2020 Feb;45(2):190-198
pubmed: 31425668
Prog Retin Eye Res. 2020 Mar;75:100799
pubmed: 31557521
Arch Ophthalmol. 1999 Nov;117(11):1540-4
pubmed: 10565524
Jpn J Ophthalmol. 1998 Sep-Oct;42(5):337-44
pubmed: 9822959
Curr Opin Ophthalmol. 2000 Apr;11(2):78-84
pubmed: 10848224
Int J Mol Sci. 2022 Feb 09;23(4):
pubmed: 35216043
Int J Mol Sci. 2019 Aug 22;20(17):
pubmed: 31443568
Can J Ophthalmol. 2017 Feb;52(1):114-124
pubmed: 28237137
Cell Death Discov. 2019 Jul 4;5:112
pubmed: 31285855
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Exp Eye Res. 2020 Nov;200:108208
pubmed: 32882213
Nutrients. 2019 Apr 30;11(5):
pubmed: 31052183
Exp Eye Res. 2006 Aug;83(2):429-37
pubmed: 16682027
J Neuroinflammation. 2016 Feb 20;13:44
pubmed: 26897546
Invest Ophthalmol Vis Sci. 2001 Nov;42(12):2849-55
pubmed: 11687528
Ophthalmic Physiol Opt. 2018 Jan;38(1):56-65
pubmed: 29168194
Brain Res. 1998 Feb 16;784(1-2):100-4
pubmed: 9518569
Sci Rep. 2017 Nov 2;7(1):14951
pubmed: 29097767
Colloids Surf B Biointerfaces. 2014 Oct 1;122:498-504
pubmed: 25082753
Exp Eye Res. 2009 Apr;88(4):752-9
pubmed: 18977348
Exp Eye Res. 1995 Sep;61(3):379-82
pubmed: 7556500
Mol Vis. 2018 Nov 16;24:733-745
pubmed: 30581280
Front Neurosci. 2020 Nov 12;14:566428
pubmed: 33281543
Invest Ophthalmol Vis Sci. 2002 Feb;43(2):402-10
pubmed: 11818384
Life Sci. 2020 Sep 1;256:117943
pubmed: 32531377
Br J Ophthalmol. 2006 Mar;90(3):262-7
pubmed: 16488940
Oxid Med Cell Longev. 2017;2017:9208489
pubmed: 28194256
Exp Eye Res. 2015 Dec;141:9-14
pubmed: 26116904
Mech Ageing Dev. 1989 Feb;47(2):145-57
pubmed: 2654504
Exp Eye Res. 2011 Aug;93(2):156-64
pubmed: 20708000
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Sep 11;:
pubmed: 30209439
Drug Dev Ind Pharm. 2019 May;45(5):745-753
pubmed: 30632800
Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2067-76
pubmed: 19959644
Prog Retin Eye Res. 2018 Jul;65:50-76
pubmed: 29481975
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):790-798
pubmed: 30892092
Korean J Ophthalmol. 1992 Jun;6(1):1-5
pubmed: 1434040
Matrix Biol. 2017 Jul;60-61:27-37
pubmed: 27496349
Sci Rep. 2014 Aug 01;4:5910
pubmed: 25081302
Pharmacol Res. 2012 Jul;66(1):19-32
pubmed: 22433276
J Cell Biol. 2007 Dec 31;179(7):1523-37
pubmed: 18158332
Exp Eye Res. 2015 Dec;141:23-32
pubmed: 26003399
Cell Transplant. 2018 Feb;27(2):213-229
pubmed: 29637819
Invest Ophthalmol Vis Sci. 2000 May;41(6):1380-5
pubmed: 10798653
PLoS One. 2017 Oct 12;12(10):e0184064
pubmed: 29023460
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6504-13
pubmed: 20688741
Am J Ophthalmol. 2015 Jul;160(1):17-25.e1
pubmed: 25892127
Biomedicines. 2021 Jun 16;9(6):
pubmed: 34208744
Mol Vis. 2011 Apr 06;17:864-75
pubmed: 21527996
Oncotarget. 2017 Aug 24;8(46):80841-80852
pubmed: 29113348
Eur J Pharmacol. 2020 Aug 15;881:173208
pubmed: 32464192
Adv Healthc Mater. 2018 Jan;7(1):
pubmed: 29171928
Stem Cell Res Ther. 2015 Sep 16;6:177
pubmed: 26377305
Exp Eye Res. 1995 Jun;60(6):697-706
pubmed: 7641852
J Control Release. 2019 Mar 10;297:26-38
pubmed: 30664980
Curr Neurol Neurosci Rep. 2018 Apr 12;18(5):25
pubmed: 29651628
Exp Eye Res. 2020 Feb;191:107920
pubmed: 31923415
Exp Eye Res. 2005 Jul;81(1):71-80
pubmed: 15978257
Pharmaceuticals (Basel). 2021 Jan 11;14(1):
pubmed: 33440745